All In Biotech

Drug Trial Radar · NCT07436234

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe SAR

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Sep 30, 2026

Study completion May 13, 2027

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • AK139Drug

    AK139 regimen 1- subcutaneous injection.

  • AK139Drug

    AK139 regimen 2- subcutaneous injection

  • PlaceboDrug

    Placebo-subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in daily reflective total nasal symptom scores (rTNSS) over 2 weeks of treatmentTime frame: Up to week 2
  2. Incidence of adverse events (AEs)Time frame: Up to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tong-Ren hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.